These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 28184913)
1. Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review). Li K; Yang M; Liang N; Li S Oncol Rep; 2017 Mar; 37(3):1347-1358. PubMed ID: 28184913 [TBL] [Abstract][Full Text] [Related]
2. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250 [TBL] [Abstract][Full Text] [Related]
3. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations. Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Wu JY; Yu CJ; Chang YC; Yang CH; Shih JY; Yang PC Clin Cancer Res; 2011 Jun; 17(11):3812-21. PubMed ID: 21531810 [TBL] [Abstract][Full Text] [Related]
5. New data on clinical decisions in NSCLC patients with uncommon EGFR mutations. Wu TH; Hsiue EH; Lee JH; Lin CC; Yang JC Expert Rev Respir Med; 2017 Jan; 11(1):51-55. PubMed ID: 27927060 [TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755 [TBL] [Abstract][Full Text] [Related]
7. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer. Zhang K; Yuan Q J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005 [TBL] [Abstract][Full Text] [Related]
8. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Gadgeel SM; Wozniak A Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287 [TBL] [Abstract][Full Text] [Related]
10. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors. Chen Q; Quan Q; Ding L; Hong X; Zhou N; Liang Y; Wu H Oncotarget; 2015 Sep; 6(28):24904-11. PubMed ID: 26172562 [TBL] [Abstract][Full Text] [Related]
11. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. Tan CS; Cho BC; Soo RA Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616 [TBL] [Abstract][Full Text] [Related]
12. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). Lee JY; Qing X; Xiumin W; Yali B; Chi S; Bak SH; Lee HY; Sun JM; Lee SH; Ahn JS; Cho EK; Kim DW; Kim HR; Min YJ; Jung SH; Park K; Mao M; Ahn MJ Oncotarget; 2016 Feb; 7(6):6984-93. PubMed ID: 26755650 [TBL] [Abstract][Full Text] [Related]
13. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. Ludovini V; Bianconi F; Pistola L; Pistola V; Chiari R; Colella R; Bellezza G; Tofanetti FR; Siggillino A; Baldelli E; Flacco A; Giuffrida D; Sidoni A; Crinò L Cancer Chemother Pharmacol; 2012 May; 69(5):1289-99. PubMed ID: 22302407 [TBL] [Abstract][Full Text] [Related]
14. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era? Ou SH; Soo RA Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839 [TBL] [Abstract][Full Text] [Related]
15. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors. Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M; Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527 [TBL] [Abstract][Full Text] [Related]
16. De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer. Takeda M; Okamoto I; Fujita Y; Arao T; Ito H; Fukuoka M; Nishio K; Nakagawa K J Thorac Oncol; 2010 Mar; 5(3):399-400. PubMed ID: 20186026 [TBL] [Abstract][Full Text] [Related]
17. EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer. Kao HF; Lin CC; Yang JC Future Oncol; 2013 Jul; 9(7):991-1003. PubMed ID: 23837762 [TBL] [Abstract][Full Text] [Related]
18. Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations. Wang Z; Shen Z; Li Z; Duan J; Fu S; Liu Z; Bai H; Zhang Z; Zhao J; Wang X; Wang J Proc Natl Acad Sci U S A; 2015 Aug; 112(32):9990-5. PubMed ID: 26216950 [TBL] [Abstract][Full Text] [Related]
19. Clinical significance of heterogeneity in response to retreatment with epidermal growth factor receptor tyrosine kinase inhibitors in patients with lung cancer acquiring secondary resistance to the drug. Lee Y; Kim HY; Lee SH; Lim KY; Lee GK; Yun T; Han JY; Kim HT; Lee JS Clin Lung Cancer; 2014 Mar; 15(2):145-51. PubMed ID: 24342626 [TBL] [Abstract][Full Text] [Related]
20. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials. Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]